Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib

Bin Zhang, David Irvine, Yin Wei Ho, Silvia Buonamici, PhD, Paul Manley, PhD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Mhairi Copland, PhD, BSc, MRCP, FRCPath, Ravi Bhatia, MD

Blood (2010) 116 (21): 514.

https://doi.org/10.1182/blood.V116.21.514.514

Published: 2010

Journal Articles

Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia.

Pierre Laneuville, MD, FRCPC, Clifford DiLea, PharmD, Jürgen Mestan, Ophelia Yin, PhD, FCP, Richard C. Woodman, MD, Paul Manley, PhD

Blood (2009) 114 (22): 510.

https://doi.org/10.1182/blood.V114.22.510.510

Published: 2009

Journal Articles

The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.

Deborah L White, PhD, Verity A Saunders, Amity Frede, Phuong Dang, Stephanie Zrim, Michael Philip Osborn, MB, BS, Paul Manley, PhD, Timothy Hughes, MD

Blood (2009) 114 (22): 507.

https://doi.org/10.1182/blood.V114.22.507.507

Published: 2009

Journal Articles

Lyn Kinase Overexpression Is One of the Mechanisms of Resistance to Nilotinib In Chronic Myeloid Leukemia

Francois-Xavi er Mahon, Sandrine Hayette, Valerie Lagarde, Franck E Nicolini, MD, PhD, Francis Belloc, Cedric Leroy, Serge Roche, Paul Manley, PhD, Coralie Belanger, Gabriel Etienne, Jean-Max Pasquet

Blood (2008) 112 (11): 3181.

https://doi.org/10.1182/blood.V112.11.3181.3181

Published: 2008

Journal Articles

Nilotinib Inhibits Bcr-Abl Kinase Activity in CML Progenitor Cells More Effectively Than Imatinib but Is Equipotent in Inducing Growth Inhibition.

Heiko Konig, Melissa Holtz, Hardik Modi, Paul Manley, Tessa L. Holyoake, Stephen J. Forman, Ravi Bhatia

Blood (2006) 108 (11): 744.

https://doi.org/10.1182/blood.V108.11.744.744

Published: 2006

Journal Articles

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Karoline Sonneck, MD, Alexandra Boehm, MD, Puchit Samorapoompichit, MD, Alexander Gruze, Winfried Pickl, Paul Manley, Doriano Fabbro, Christian Sillaber, Peter Valent

Blood (2005) 106 (11): 3523.

https://doi.org/10.1182/blood.V106.11.3523.3523

Published: 2005

Journal Articles

Low Baseline Intrinsic Sensitivity to Imatinib (High IC50) in CML Patients Is Due to Reduced Oct-1 Mediated Influx. Intrinsic Sensitivity to AMN107 Does Not Correlate with That of Imatinib and Uptake of AMN107 Is Not Oct-1 Mediated.

Deborah L. White, Verity A. Saunders, Jane Engler, Phuong Dang, Andrew C.W. Zannettino, Antony Cambareri, Steven Quinn, Paul Manley, Timothy P. Hughes

Blood (2005) 106 (11): 1081.

https://doi.org/10.1182/blood.V106.11.1081.1081

Published: 2005

Journal Articles

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Mirna Golemovic, M.S., Miloslav Beran, M.D., Ph.D., Francis Giles, M.D., Taghi Manshouri, M.S.C., Deborah Thomas, M.D., Jorge Cortes, M.D., Paul Manley, M.D., Leila Alland, M.D., Patricia Rae, B.S.C., Margaret Dugan, M.D., Zeev Estrov, M.D., Ralph B. Arlinghaus, Ph.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2004) 104 (11): 2737.

https://doi.org/10.1182/blood.V104.11.2737.2737

Published: 2004

Journal Articles

Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells.

Anna Scuto, Ph.D., Srinivas Annavarapu, M.S., Purva Bali, M.S., Molly McCullers, Warren Fiskus, Ph.D., Abdelmoughite Mouttaki, B.S., Fei Guo, Ph.D., Celia Sigua, M.S., Gautam Sondarva, Ph.D., Peter Atadja, Ph.D., Paul Manley, Ph.D., Kapil N. Bhalla, M.D.

Blood (2004) 104 (11): 1977.

https://doi.org/10.1182/blood.V104.11.1977.1977

Published: 2004

Journal Articles

Molecular Characterization of Human CML Cells with Resistance to the Heat Shock Protein (hsp) 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin (17-AAG).

Purva Bali, M.S., Warren Fiskus, Ph.D., Fei Guo, Ph.D., Srinivas Annavarapu, M.S., Celia Sigua, M.S., Gautam Sondarva, Ph.D., Abdelmoughite Mouttaki, B.S., Peter Atadja, Ph.D., Paul Manley, Ph.D., Kapil N. Bhalla, M.D.

Blood (2004) 104 (11): 1980.

https://doi.org/10.1182/blood.V104.11.1980.1980

Published: 2004

Journal Articles

Activity and Induction of Apoptosis of the Specific Tyrosine Kinase Inhibitor AMN 107 in bcr-abl + Cell Lines and in Imatinib Resistant Primary Cells from CML Patients.

Philipp Le Coutre, MD, Gökben Baskaynak, MD, Ingo Tamm, MD, Jörg Westermann, MD, Justus Duyster, MD, Malte v. Bonin, MD, Stefan Pursche, MD, Petra Mayer, MD, Paul Manley, Ph.D., Jürgen Mestan, Ph.D., Eberhard Schleyer, M.D., Bernd Dorken, M.D.

Blood (2004) 104 (11): 762.

https://doi.org/10.1182/blood.V104.11.762.762

Published: 2004

NARROW

Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib

Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia.

The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.

Lyn Kinase Overexpression Is One of the Mechanisms of Resistance to Nilotinib In Chronic Myeloid Leukemia

Nilotinib Inhibits Bcr-Abl Kinase Activity in CML Progenitor Cells More Effectively Than Imatinib but Is Equipotent in Inducing Growth Inhibition.

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Low Baseline Intrinsic Sensitivity to Imatinib (High IC50) in CML Patients Is Due to Reduced Oct-1 Mediated Influx. Intrinsic Sensitivity to AMN107 Does Not Correlate with That of Imatinib and Uptake of AMN107 Is Not Oct-1 Mediated.

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells.

Molecular Characterization of Human CML Cells with Resistance to the Heat Shock Protein (hsp) 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin (17-AAG).

Activity and Induction of Apoptosis of the Specific Tyrosine Kinase Inhibitor AMN 107 in bcr-abl + Cell Lines and in Imatinib Resistant Primary Cells from CML Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only